Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode Ltd. (INMD) announced expectations for record financial results in Q2 2022, forecasting revenue between $113.0 million to $113.3 million. The company anticipates a non-GAAP earnings per diluted share of $0.57 to $0.58. Additionally, InMode raised its full-year revenue guidance to a range of $425 million to $435 million, up from a previous range of $415 million to $425 million. The company attributes this growth to strong demand for its medical technologies in aesthetic surgery.
InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness technology in Canada after receiving certification from Health Canada. This advancement aims to improve urinary incontinence symptoms (SUI) and builds upon existing licenses for Genitourinary Syndrome of Menopause (GSM) and chronic pelvic pain. The EmpowerRF platform offers advanced therapies, including intravaginal electrical muscle stimulation and bipolar radiofrequency. InMode emphasizes its commitment to enhancing women's health through effective, minimally invasive solutions. This initiative reflects a strategic milestone for InMode in the global healthcare market.
InMode Ltd. (Nasdaq: INMD), a prominent global provider of innovative medical technologies, announced participation in the UBS Healthcare One-on-One Virtual Day on June 1, 2022. CEO Moshe Mizrahy and CFO Yair Malca will represent the company. Interested parties can schedule meetings through their UBS representative or by contacting Miri Segal at msegal@ms-ir.com. InMode specializes in medical devices using radiofrequency technology, serving various medical fields including plastic surgery and dermatology.
InMode Ltd. (NASDAQ: INMD) reported Q1 2022 revenues of $85.9 million, a 31% year-over-year increase. GAAP net income was $31 million, reflecting a 16% rise from the prior year, achieving GAAP diluted EPS of $0.36. The company noted record consumable revenues of $14 million, up 79% year-over-year. Despite facing global supply chain challenges affecting gross margins, management reiterated a full-year revenue guidance of $415-$425 million and robust long-term gross margin targets of 84%-86%.
InMode Ltd (Nasdaq: INMD) announced its expected financial results for Q1 2022, projecting revenue between $85.0 million and $85.5 million and non-GAAP earnings per diluted share between $0.38 and $0.39. The company noted an 83% to 84% gross margin, reflecting growth in demand for its minimally invasive solutions. Despite challenges from COVID-19 variants and supply chain issues, InMode managed to maintain productivity and meet delivery expectations. A conference call is scheduled for May 2, 2022, to discuss the results further.
InMode Ltd. (Nasdaq: INMD), a leading provider of innovative medical technologies, will participate in a virtual fireside chat at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 4:30 p.m. ET. The event will feature CEO Moshe Mizrahy, CFO Yair Malca, and CMO Dr. Spero Theodorou, hosted by CFA Mike Matson. Management will also hold one-on-one meetings that day. A live link for the chat is available here, with more info on InMode's investor relations site.
InMode Ltd. (Nasdaq: INMD) announced a new share repurchase program, approving the buyback of up to 1 million ordinary shares. This decision follows the successful completion of a previous buyback in September 2020, reflecting the company's confidence in its long-term outlook. The program, funded by available cash, aims to enhance shareholder value and follows a trend of fiscally responsible investments. The board emphasized strong cash flow and a robust balance sheet as key factors justifying the buyback.
InMode Ltd. (Nasdaq: INMD) announced participation in two investor conferences in March 2022. The company will host a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15, at 10:40 a.m. EST. Additionally, InMode will present in-person at the Barclays Global Healthcare Conference on March 17, at 9:00 a.m. EST, located at the Loews Miami Beach Hotel. These events provide opportunities for one-on-one meetings with investors. For further details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported strong financial results for Q4 and FY 2021, with quarterly revenues reaching a record $110.5 million, a 47% increase year-over-year. The company achieved a GAAP net income of $52.7 million for Q4, and $165 million for the full year, compared to $75 million in 2020. Full year revenues totaled $357.6 million, a 73% increase. The company expects revenues for 2022 in the range of $415-$425 million with non-GAAP earnings per diluted share between $2.06 and $2.11. InMode continues to expand internationally and maintain healthy gross margins of 85%.
InMode Ltd. (Nasdaq: INMD) announced its anticipated financial results for the fourth quarter and full year 2021, revealing record revenues. The company expects fourth quarter revenue between $109.5M and $110M, and full year revenue of $356.5M to $357M, surpassing earlier guidance of $343M to $347M. Non-GAAP earnings per diluted share are forecasted at $0.61 for Q4 and $2.02 to $2.03 for the full year. Looking ahead, InMode projects 2022 revenues between $415M and $425M.